Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.

Dietz-Fricke, Christopher; Tacke, Frank; Zöllner, Caroline; Demir, Münevver; Schmidt, Hartmut H.; Schramm, Christoph; Willuweit, Katharina; Lange, Christian; Weber, Sabine;
Denk, Gerald Ulrich; Berg, Christoph P.; Grottenthaler, Julia M.; Merle, Uta; Olkus, Alexander; Zeuzem, Stefan; Sprinzl, Kathrin; Berg, Thomas; van Bömmel, Florian; Wiegand, Johannes; Herta, Toni; Seufferlein, Thomas; Zizer, Eugen;
Dikopoulos, Nektarios; Thimme, Robert; Neumann-Haefelin, Christoph; Galle, Peter R; Sprinzl, Martin; Lohse, Ansgar W.; Schulze zur Wiesch, Julian; Kempski, Jan; Geier, Andreas; Reiter, Florian P.; Schlevogt, Bernhard; Gödiker, Juliana; Hofmann, Wolf Peter; Buggisch, Peter; Kahlhöfer, Julia; Port, Kerstin; Maasoumy, Benjamin; Cornberg, Markus; Wedemeyer, Heiner;
Deterding, Katja

Background & aims

Bulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen. In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepatocellular carcinoma. Herein, we report the first data from a large multicenter real-world cohort of patients with hepatitis D treated with bulevirtide at a daily dose of 2 mg without additional interferon.


In a joint effort with 16 hepatological centers, we collected anonymized retrospective data from patients treated with bulevirtide for chronic hepatitis D.


Our analysis is based on data from 114 patients, including 59 (52%) with cirrhosis, receiving a total of 4,289 weeks of bulevirtide treatment. A virologic response defined as an HDV RNA decline of at least 2 log or undetectable HDV RNA was observed in 87/114 (76%) cases with a mean time to virologic response of 23 weeks. In 11 cases, a virologic breakthrough (>1 log-increase in HDV RNA after virologic response) was observed. After 24 weeks of treatment, 19/33 patients (58%) had a virologic response, while three patients (9%) did not achieve a 1 log HDV RNA decline. No patient lost hepatitis B surface antigen. Alanine aminotransferase levels improved even in patients not achieving a virologic response, including five patients who had decompensated cirrhosis at the start of treatment. Treatment was well tolerated and there were no reports of drug-related serious adverse events.


In conclusion, we confirm the safety and efficacy of bulevirtide monotherapy in a large real-world cohort of patients with hepatitis D treated in Germany. Future studies need to explore the long-term benefits and optimal duration of bulevirtide treatment.

Impact and implications

Clinical trials proved the efficacy of bulevirtide for chronic hepatitis D and led to conditional approval by the European Medical Agency. Now it is of great interest to investigate the effects of bulevirtide treatment in a real-world setting. In this work, we included data from 114 patients with chronic hepatitis D who were treated with bulevirtide at 16 German centers. A virologic response was seen in 87/114 cases. After 24 weeks of treatment, only a small proportion of patients did not respond to treatment. At the same time, signs of liver inflammation improved. This observation was independent from changes in hepatitis D viral load. The treatment was generally well tolerated. In the future, it will be of interest to investigate the long-term effects of this new treatment.


Citation style:
Could not load citation form.

Access Statistic

Last 12 Month:


Use and reproduction: